China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the target of a large decrease in short interest in October. As of October 30th, there was short interest totaling 28,225 shares, a decrease of 96.1% from the October 15th total of 721,044 shares. Based on an average daily volume of 716,620 shares, the days-to-cover ratio is presently 0.0 days. Currently, 564.5% of the company’s stock are short sold.
Analysts Set New Price Targets
Several brokerages have commented on SXTC. Wall Street Zen upgraded shares of China SXT Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings cut shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, China SXT Pharmaceuticals has an average rating of “Sell”.
China SXT Pharmaceuticals Price Performance
Shares of SXTC stock traded down $0.22 on Tuesday, hitting $2.88. 92,825 shares of the stock were exchanged, compared to its average volume of 499,381. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $127.92 and a 200 day moving average of $12,490.24. China SXT Pharmaceuticals has a fifty-two week low of $2.71 and a fifty-two week high of $8,375,880.00.
China SXT Pharmaceuticals Company Profile
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance. Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.
See Also
- Five stocks we like better than China SXT Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
